Applicants:

Liu. et al.

Serial No.

09/831,580

Filed: September 28, 2001

For: G PROTEIN-COUPLED RECEPTOR RESEMBLING

LEUKOTRIENE B4 RECEPTOR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SED 24 2003

TECH CENTER 1600 2900

Examiner:

Murphy

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

INFORMATION DISCLOSURE STATEMENT

FOR CENTRAL PROPERTY AND A SERVICE OF SERVI by the Office in a related application upon which the instant application relies for an earlier filing date under 35 6.00. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED AP	PLICATION
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
		-
		-

If this is inconvenient, additional copies will be submitted upon request.

	6. In accordance with 37 C.F.R. 1.97, (check one)
	the attached information is filed within three months of the filing date of the captioned case.
/	the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
	the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p). the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
	the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

By: Vineet Kohli

Attorney For Applicant(s)

Reg. No. 37,003

MERCK & CO., INC. Patent Dept., RY60-30

P.O. Box 2000

Dahway N I DZORE DOOZ

					COMPLETE IF KNOWN					
	Substitute for form 1449A-PTO INFORMATION DISCLOSURE		Application Number	09 831,580						
	INFORMATION DISCLOSURE					September 29, 2001 RECEIVE				
STATEMENT BY APPLICANT				PLICANT	First Named Inventor	Liu Sca				
					Group Art Unit	1646				
(use as many sheets as necessary)		Examiner Name	Murphy IECH CE 723							
Shee			of	4	Attorney Docket Number	20332Р				
Succ	- t	·								

		U.S. Patent Document	<u> </u>	ATENT DOCUMENTS	Date of Publication of
xaminer nitials*	Cite No.	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
		5,552,441	- (i) known)	Dillard, et al.	09/03/1996
				Djuric, et al.	11/04/1997
		5,684,162		Djane, et an	
	 				
	<u> </u>				
	-				
	+				
	+-				

FOREIGN PATENT DOCUMENTS									
			Foreign Patent Document		Name of Patentee or Applicant	Date of Publication of Cited Document			
ixaminer nitials*	Cite No.	Office	Number	Kind Code (1) known)	of Cited Document	MM-DD-YYYY			
		 							
		1 1							

Lxammer	Date Considered
Signature	

C. hattite for form 1410R RTC				COMPLETE IF KNOWN					
	Substitute for form 1449B PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	09 831,580 P F				
				Filing Date	September 29, 2001 CE/VE-				
S	TATEMENT BY	' AP	PLICANT	First Named Inventor	Liu SEP 2				
7 1 77	ή? -			Group Art Unit	16467FOUR				
(use as many sheets as necessary)				Examiner Name	Murphy Co. 767				
Sheet	2	of	4	Attorney Docket Number	20332P				

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Cunningham, et al., "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis", Science, Vol. 244, pp. 1081-1085, (1989).
		DeGiulio, et al., "Increased Levels of Leukotriene β4 and Interleukin-8 in Psoriatic Skin", Ann. New York Acad. Sci., Vol. 685, pp. 614-617 (1993).
		Dohlman, et al., "Model Systems for The Study of Seven-Transmembrane-Segment Receptors", Annu. Rev. Biochem., Vol. 60, pp. 653-688 (1991),
		Ford-Hutchinson, et al., "Leukotriene B, a potene chemokinetic and aggregating substance released from polymorphonuclear leukocytes", Vol. 286, pp. 265-268 (1980).
		Gladue, et al., "Inhibition of Leukotriene B4-Receptor Interaction Suppresses Eosinophil Infiltration and Disease Pathology in a Murine Model of Experimental Allergic Encephalomyelitis", J. Exp. Med., Vol. 183, pp. 1983-1898 (1996).
		Graminski, et al., "Pigment Dispersion in Frog <elanophores (1993).<="" 265,="" 5957-5964="" 8,="" a="" activates="" be="" by="" c",="" can="" ester="" induced="" no.="" of="" or="" phorbol="" phospholipase="" pp.="" receptor="" recombinant="" stimulation="" td="" that="" vol.=""></elanophores>
		Goetzl & Pickett, "The Human PMN Leukocyte Chemotactic Activity of Complex Hydroxy-Eicosatetraenoic Acids (HETEs)", J. of Immunol., Vol. 125, No. 4, pp. 1789-1791 (1980).
		Hebert, et al., "A Peptide Derived from a β2-Adrenergic Receptor Transmembrane Domain Inhibits Both Receptor Dimerization and Activation", J. Biol. Chem., Vol. 271, pp. 16384-16392 (1996).
		Hess, et al., "Cloning and Pharmacological Characterization of a Human Bradykinin (BK-2) Receptor", Vol. 184, No. 1, pp. 260-268 (1992).
		Hodgson, "Receptor Screening and the Search for New Pharmaceuticals", Vol. 10, pp. 973-980 (1992).
		Hopp & Woods, "Prediction of protein antigenic determinants from amino acid sequences", Proc. Natl. Acad. Sci. USA, Vol. 78, No. 6, pp. 3824-3828 (1981).
		Howard, et al., "A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release", Science, Vol. 273, pp. 974-977 (1996).
		Ioannou, et al., "A new bacteriophage P1-derived vector for the propagation of large human DNA fragments", Nature Genet., Vol. 6, No. 1, pp. 84-89 (1994).
		Jameson, et al., "The antigenic index: a novel algorithm for prediction antigenic determinants", CABIOS, Vol. 4 No. 1 pp. 181-186 (1988)

	Date
Examiner	Considered
Signature	Considered
- 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	

					COMPLETE IF KNOWN		
	ubstitute for form 1449B/PTO NFORMATION	DIS	CLOSURE	Application Number	09 831,580		
. •				Filing Date	September 29, 2001		
STATEMENT BY APPLICANT				First Named Inventor	Liu		
7 7 7	•			Group Art Unit	1646 RECEIVED		
(use as many sheets as necessary)				Examiner Name	Murphy SEP 2 4 2203		
Sheet	3	of	4	Attorney Docket Number			

		NON PATENT LITERATURE DOCUMENTS LUTT VILLE MAN 16.79, 2000
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
minais	.10.	Lerner, "Tools for investigating functional interactions between ligands and G-protein-coupled receptors", Trends Neurosci., Vol. 17, pp. 142-146 (1994).
		McKee, et al., Molecular Analysis of Rat Pituitary and Hypothalamic Growth Hormone Secretagogue Receptors", Mol. Endocrinol., Vol. 11, pp. 415-423 (1997).
		Neu, et al., "Leukotrienes in the cerebrospinal fluid of multiple sclerosis patients", Vol. 86, pp. 586-587 (1992).
		Ng, et al., "Dopamine D2 Receptor Dimers and Receptor-Blocking Peptides", Biochem. Biophys. Res. Comm., Vol. 227, pp. 200-204 (1996).
		Offermanns & Simon, "Ga15 and Ga16 Couple a Wide Variety of Receptors to Phospholipase C*", J. Biol. Chem., Vol. 270, pp. 15175-15180 (1995).
		Potenza & Lerner, "A Rapid Quantitative Bioassay for Evaluating the Effects of Ligands Upon Receptors That Modulate cAMP Levels in a Melanophore Cell Line", Pigment Cell Research., Vol. 5, pp. 372-378 (1992).
		Palmer, et al., "Chemokinetic Activity of Arachidonic Acid Lipoxygenase Products on Leuocyctes of Different Species", Vol. 20, No. 2, pp. 411-418 (1980).
		Romano, et al "Metabotropic Glutamate Receptor 5 is a Disulfide-linked Dimer", J. Biol. Chem., Vol. 271, Vol. 45, pp. 28612-28616)1996).
		Schertler, et al., "Projection structure of rhodopsin", Nature, Vol. 362, pp. 770-772 (1993).
		Strader, et al., "Structure and Function of G Protein-Coupled Receptors", Ann. Rev. Ciochem., Vol. 63, pp. 101-132 (1994).
		Tan & Spector, "Antileukotriene Agents in Asthma", Science & Medicine, pp. 26-33 (July/August, 1997).
		Yokomizo, et al., "A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis", Nature, Vol. 387, pp. 620-624 (1997).
		Science, Vol. 265, pp. 1891-2144 (1994).
	+ -	Verma, et al., Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY

. 1.	C Bellialinin S of L				

Examiner	Date Considered	
Signaliae		_

	Substitute for form 1449B PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT SP 2 2 7003		COMPLETE IF KNOWN			
			Application Number	09 831.5	80	
			Filing Date	September 29, 20 RECEIVED		
			First Named Inventor	Liu	TECEIVED	
Eb 3 (Group Art Unit	1646	SEP 2 4 7003	
(use as many sheets as necessary)		Examiner Name	Murphy	TECH OF HOUSE LOSS		
Shee	4	of	4	Attorney Docket Number	20332P	TECH CENTER 1600,2900

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.		
		GenBank Accession No. D89078		
		GenBank Accession No. D89079		
		Showell, et al., "The Preclinical Pharmacological Profile of the Potent and Selective Leukotriene B4 Antagonist CP-195543", J. Pharmacol. and Experi. Theraptutics, Vol. 285, No. 3, pp. 946-954.		
		Forster, et al., "A general method for screening mAbs specific for G-protein coupled receptors as exemplified by using epitope tagged BLR1-transfected 293 cells and solid-phase cell ELISA", Biochem. Biophys. Res. Comm., Vol. 196, No. 3, pp. 1496-1503 (1993).		
		Strategene - Gene Characterization, pp. 66 (1991).		
,	-			

Examiner	1	Date
Signature		* Considered